目的 采用meta分析评价生脉注射液辅助治疗冠心病心力衰竭患者有效性和安全性。方法 利用计算机检索ProQuest、PubMed、Cochrane Library、Embase、Springer Link、Web of Science、中国知网、万方数据知识服务平台、维普、中国生物医学文献数据库中生脉注射液治疗冠心病心力衰竭的临床随机试验，检索时限为建库至2024年2月。2名人员独立筛选文献、提取资料并对纳入文献进行方法学质量评价，并采用RevMan 5。3软件进行meta分析。结果 共纳入15篇RCT文献，样本量1412例，meta分析结果显示，与对照组比较，试验组产生的不良反应更少(RR=0。38，95％CI:0。18，0。79，P<0。05)，总有效率更高(RR=1。19，95％CI:1。14，1。24，P<0。05)，且试验组可提高冠心病心力衰竭患者的左室射血分数(MD=9。49，95％CI:6。40，12。59，P<0。00001)，降低左室收缩末期直径(MD=-6。24，95％CI:-8。15，-4。33，P<0。00001)。结论 生脉注射液辅助常规治疗比单纯常规治疗冠心病心力衰竭患者有效性和安全性更好，在临床上值得进一步推广。
Meta-analysis of efficacy and safety of Shengmai injection in adjuvant treatment of patients with coronary heart disease and heart failure
Objective To evaluate the efficacy and safety of Shengmai injection in adjuvant treatment of patients with coronary heart disease and heart failure by meta-analysis. Methods The clinical randomized trials of Shengmai injection in the treatment of coronary heart disease and heart failure were searched by computer from ProQuest,PubMed,Cochrane Library,Embase,Springer Link,Web of Science,China National Knowledge Infrastructure,Wanfang,VIP and China Biomedical Literature Database,with a search period from database establishment to February 2024. Two individuals independently screened literature,extracted data,and evaluated the methodological quality of the included literature,and conducted meta-analysis using RevMan 5.3 software. Results A total of 15 RCT articles were included,with a sample size of 1412 cases. Meta-analysis showed that compared with the control group,the experimental group had fewer adverse reactions (RR=0.38,95％CI:0.18,0.79,P<0.05) and the total effective rate was higher (RR=1.19,95％CI:1.14,1.24,P<0.05). And the experimental group can improve the left ventricular ejection fraction (MD=9.49,95％CI:6.40,12.59,P<0.00001) and decrease the left ventricular end systolic diameter (MD=-6.24,95％CI:-8.15,-4.33,P<0.00001). Conclusion The combination of Shengmai injection and conventional treatment is more effective and safe than conventional treatment alone for patients with coronary heart disease and heart failure,and it is worth further promotion in clinical practice.
Coronary heart disease and heart failureShengmai injectionMeta-analysisEfficacySafety
万方数据
维普
